Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
3 High-Yielding Dividend Stocks That Are Trading at Dirt-Cheap Valuations
05:23am, Saturday, 20'th Apr 2024
Bristol Myers has an uncertain future, but with a strong track record and impressive cash flow it's still a top healthcare stock to own. Verizon Communications offers investors a mouth-watering yield
Got $500? 3 Healthcare Stocks to Buy and Hold Forever
08:15am, Friday, 19'th Apr 2024
Healthcare stocks can be excellent choices for investors, offering a balance of safety and growth. Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk all have strong growth potential.
3 Undervalued Dividend Stocks to Buy Now to Beat the S&P 500
03:20pm, Wednesday, 17'th Apr 2024
The U.S. stock market continues to climb the wall of worry, despite persistent inflation and heightened geopolitical risks. The S&P 500 has returned 26% in the past 12 months, while the Wilshire 5000
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years
09:30am, Wednesday, 17'th Apr 2024
Bristol Myers Squibb is turning on its innovative machine to get through recent patent cliffs. Novartis recently became a thinner company that is laser-focused on developing new medicines.
Bristol Myers Squibb (BMY) Advances While Market Declines: Some Information for Investors
06:56pm, Monday, 15'th Apr 2024
Bristol Myers Squibb (BMY) closed the most recent trading day at $48.51, moving +0.48% from the previous trading session.
3 Pharma Stocks That Are Money-Printing Machines in 2024
05:51pm, Monday, 15'th Apr 2024
The future of the U.S. economy appears promising, with robust growth and strong corporate performance. This economic strength has propelled the stock market to record highs, signaling confidence in th
Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF?
09:30am, Monday, 15'th Apr 2024
Big pharma stocks, on balance, haven't been market-beating vehicles in quite some time. Bristol Myers Squibb, a top U.S. pharma company, reflects this harsh reality, with its shares trading in bargain
6 Ultimate Dividend Stocks for Long-Term Passive Income Growth
08:50am, Sunday, 14'th Apr 2024
Sponsored: Find a Qualified Financial Advisor Finding a qualified financial advisor doesn't have to be hard.
Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade)
12:06pm, Friday, 12'th Apr 2024
Bristol Myers Squibb's share price continues to move sideways despite several regulatory approvals for its innovative drugs in the past six months. On April 2, 2024, the EMA approved Reblozyl as a fir
US biopharma first quarter earnings seen stable amid low expectations
11:47am, Friday, 12'th Apr 2024
Expectations for US biopharma companies' first quarter earnings are low given the typical seasonality across the sector and new healthcare plan signups, analysts at the Bank of America believe. “We
Wall Street Favorites: 3 Warren Buffett Stocks With Strong Buy Ratings for April 2024
07:00am, Friday, 12'th Apr 2024
Many investors are hearing that we are in a stock picker's market. If that's the case, then why not take your lead from Warren Buffett?
If You Can Only Buy One Biotech Stock in April, It Better Be One of These 3 Names
01:49pm, Thursday, 11'th Apr 2024
Biotech stocks are one of the hottest investing opportunities in the stock marketlately. The optimism surrounding the industry is evident in the SPDR S&PBiotech ETF's (NYSEARCA: XBI ) 25% bump in valu
Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing
06:56pm, Tuesday, 09'th Apr 2024
In the latest trading session, Bristol Myers Squibb (BMY) closed at $51.60, marking a +0.98% move from the previous day.
Healthy Returns: J&J cell therapy gains new edge over Bristol Myers rival
02:37pm, Tuesday, 09'th Apr 2024
J&J's cell therapy is now approved for an earlier line of treatment than a competing drug from Bristol Myers. Meanwhile, a look at Mount Sinai's approach to AI.
Bristol Myers (BMY) Reports Positive Colorectal Cancer Study Data
02:30pm, Tuesday, 09'th Apr 2024
Bristol Myers' (BMY) Krazati, in combination with cetuximab, demonstrates clinically meaningful activity as a targeted treatment option for patients with previously treated KRASG12C-mutated locally ad
